At progression 2, CD163+ cell segments had DEGs such as MERTK, which has been proposed as a possible target in CTCL [57], and other immune-related molecules such as IL18, IL7R, CCL28, the signal transduction AXL Receptor Tyrosine Kinase (AXL), the transmembrane protein 163 (TMEM163), alcohol dehydrogenases (ADH1A/B/C), the scavenger receptor, ADORA2A, SIGLEC8 involved in cellular interaction and signaling, the adaptor protein, disabled-2 (DAB2), and the brain-derived neurotrophic factor (BDNF [58]). The gene discussed is ADH1A; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.